| Company Name: | ADVENTRX Pharmaceuticals, Inc. | | Ticker Symbol: | ANX | | | WWW Address: | www.adventrx.com | | CEO: | Brian M. Culley, M.S. | | No. of Employees: | 14 | | Common Issue Type: | CS | | Business Description: | A development-stage biopharmaceutical company, whose fundamental business is focused on in-licensing, developing and commercializing proprietary product candidates for the treatment of cancer.
|
| | | Industry Information: | DRUGS - Biotechnology [more like this] |
| | Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 0.1 |  0.0 | 0.0701 | 0.14 | 0.0968 | 0.10 | 0.09 | 1208365 |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 15.4 | 153.8 | -0.04 | -0.30 | 0.00 | 0.0 | 0.0 | 0.25 - 0.07 |
| | KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 0.10 | $ | | PE Ratio - LTM | 0.0 | |
| Market Capitalisation | 15.4 | mil |
| Latest Shares Outstanding | 153.8 | mil |
| Earnings pS (EPS) | -0.30 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | 0 | % |
| Revenue per Employee | 35,714 | $ |
| Effective Tax Rate | 0.0 | % |
| Float | 99.6 | mil |
| Float as % of Shares Outstanding | 92.0 | % |
| Foreign Sales | 0 | mil |
| Domestic Sales | 0 | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 798.50 | % |
| Research & Devlopment (R&D) as % of Revenue | 1,174.40 | % |
| Gross Profit Margin | 0.0 | % |
| EBITDA Margin | 0.0 | % |
| Pre-Tax Profit Margin | 0.0 | % |
| Assets Turnover | 0.1 | % |
| Return on Assets (ROA) | -407.7 | % |
| Return on Equity (ROE) | 0.0 | % |
| Return on Capital Invested (ROCI) | -961.2 | % |
| Current Ratio | 1.7 | |
| Leverage Ratio (Assets/Equity) | 2.4 | |
| Interest Cover | 0.0 | |
| Total Debt/Equity (Gearing Ratio) | 0.00 | |
| LT Debt/Total Capital | 0.0 | % |
| Working Capital pS | 0.01 | $ |
| Cash pS | 0.02 | $ |
| Book-Value pS | 0.01 | $ |
| Tangible Book-Value pS | 0.01 | $ |
| Cash Flow pS | -0.11 | $ |
| Free Cash Flow pS | -0.10 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 9.47 | |
| Price/Tangible Book Ratio | 9.47 | |
| Price/Cash Flow | -0.9 | |
| Price/Free Cash Flow | -1.0 | |
| P/E as % of Industry Group | 0.0 | % |
| P/E as % of Sector Segment | 0.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | - |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | | | | | PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | -9.1 | 91 | 22,652 | 103,149 |
| 4 Weeks | 0.14 | 0.09 | 0.13 | -23.1 | 76 | 21,677 | 433,533 |
| 13 Weeks | 0.22 | 0.09 | 0.15 | -34.2 | 62 | 27,239 | 1,743,328 |
| 26 Weeks | 0.25 | 0.09 | 0.13 | -23.1 | 63 | 33,996 | 4,317,527 |
| 52 Weeks | 0.25 | 0.07 | 0.09 | 11.1 | 81 | 24,203 | 6,074,974 |
| YTD | 0.25 | 0.07 | - | 33.3 | 110 | 26,608 | 5,986,880 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 0.10 | 0.10 | 0.13 | 0.14 | 0.14 | -0.04 | -0.14 |
| | | | GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | 0.00 | 0.0 | 0.00 |
| Income | 0.00 | 0.0 | 0.00 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | 12.46 | NA | -35.36 |
| R&D | 40.91 | NA | 1.59 |
| Normalized Inc. | 0.00 | NA | 0.00 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | 0.0 | 0.0 | 0.0 |
| Earnings % | 0.0 | 0.0 | 0.0 |
| EPS % | 0.0 | 0.0 | 0.0 |
| EPS $ | 0.11 | 0.06 | -0.05 |
| | | | SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 53.56 |
| Current Ratio | 2.2 |
| Quick Ratio (Acid Test) | 2.1 |
| Liquidity Ratio (Cash) | 2.09 |
| Receivables Turnover | 5.2 |
| Average Collection Period | 69 |
| Working Capital/Equity | 95.7 |
| Working Capital pS | 0.06 |
| Cash-Flow pS | -0.29 |
| Free Cash-Flow pS | -0.26 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | -9.09 |
| Financial Leverage Ratio (Assets/Equity) | 1.8 |
| Debt Ratio | 44.0 |
| Total Debt/Equity (Gearing Ratio) | 0.00 |
| LT Debt/Equity | 0.00 |
| LT Debt/Capital Invested | 0.0 |
| LT Debt/Total Liabilities | 0.0 |
| Interest Cover | 0.0 |
| Interest/Capital Invested | 0.00 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 2.20 |
| Tobin's Q Ratio | 1.44 |
| Current P/E Ratio - LTM | 0.00 |
| Enterprise Value (EV)/EBITDA | -0.38 |
| Enterprise Value (EV)/Free Cash Flow | -0.25 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | 9.47 |
| Price/Book Ratio - LTM | 9.47 |
| Price/Cash Flow Ratio | -0.9 |
| Price/Free Cash Flow Ratio - LTM | -1.0 |
| Price/Sales Ratio | 19.23 |
| P/E Ratio (1 month ago) - LTM | 0.0 |
| P/E Ratio (26 weeks ago) - LTM | 0.0 |
| P/E Ratio (52 weeks ago) - LTM | 0.0 |
| 5-Y High P/E Ratio | 0.0 |
| 5-Y Low P/E Ratio | 0.0 |
| 5-Y Average P/E Ratio | 0.0 |
| Current P/E Ratio as % of 5-Y Average P/E | 0 |
| P/E as % of Industry Group | 0.0 |
| P/E as % of Sector Segment | 0.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 0.0 |
| PER SHARE FIGURES |
| LT Debt pS | 0.00 |
| Current Liabilities pS | 0.05 |
| Tangible Book Value pS - LTM | 0.01 |
| Book Value pS - LTM | 0.01 |
| Capital Invested pS | 0.04 |
| Cash pS - LTM | 0.02 |
| Cash Flow pS - LTM | -0.11 |
| Free Cash Flow pS - LTM | -0.10 |
| Earnings pS (EPS) | -0.30 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | -4,770.60 |
| Free Cash Flow Margin 5YEAR AVG | -2,224.10 |
| Net Profit Margin | 0.0 |
| Net Profit Margin - 5YEAR AVRG. | 0.0 |
| Equity Productivity | 0.08 |
| Return on Equity (ROE) | 0.0 |
| Return on Equity (ROE) - 5YEAR AVRG. | 0.0 |
| Capital Invested Productivity | 0.08 |
| Return on Capital Invested (ROCI) | -444.5 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | -178.1 |
| Assets Productivity | 0.00 |
| Return on Assets (ROA) | -248.8 |
| Return on Assets (ROA) - 5YEAR AVRG. | -81.0 |
| Gross Profit Margin | 0.0 |
| Gross Profit Margin - 5YEAR AVRG. | 0.0 |
| EBITDA Margin - LTM | 0.0 |
| EBIT Margin - LTM | 0.0 |
| Pre-Tax Profit Margin | 0.0 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 0.0 |
| Effective Tax Rate | 0.0 |
| Effective Tax Rate - 5YEAR AVRG. | 0.0 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 88 |
| Revenue per Employee | 35,714 |
| Net Income per Employee | -1,903,357 |
| Average Collection Period | 88 |
| Receivables Turnover | 5.2 |
| Day's Inventory Turnover Ratio | 0 |
| Inventory Turnover | 0.0 |
| Inventory/Sales | 0.0 |
| Accounts Payble/Sales | 344.20 |
| Assets/Revenue | 0.00 |
| Net Working Capital Turnover | 0.09 |
| Fixed Assets Turnover | 1.92 |
| Total Assets Turnover | 0.0 |
| Revenue per $ Cash | 0.05 |
| Revenue per $ Plant | 2.51 |
| Revenue per $ Common Equity | 0.08 |
| Revenue per $ Capital Invested | 0.08 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 1944.0 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 3455.5 |
| Research & Devlopment (R&D) as % of Revenue | 3584.4 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 3584.4 |
|
|  
| | |  |  | |
| |